Orchestra Biomed Holdings Inc expected to post a loss of 39 cents a share - Earnings Preview

Orchestra Biomed Holdings

31/07/2026 23:54

Orchestra Biomed Holdings Inc OBIO.OQ OBIO.O is expected to  show a fall in quarterly revenue when it reports  results on August 3 (estimated) for the period ending June 30 2026
The New Hope Pennsylvania-based  company is expected to report a 85.5% decrease in revenue to $121.4 thousand from $836 thousand a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Orchestra Biomed Holdings Inc is for a loss of 39 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Orchestra Biomed Holdings Inc is $10.00, about 151.3% above its last closing price of $3.98
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.43
-0.43
-0.33
Beat
23.4
Dec. 31 2026
-0.37
-0.38
-0.13
Beat
65.7
Sep. 30 2025
-0.39
-0.43
-0.40
Beat
8​
Jun. 30 2025
-0.50
-0.50
-0.50
Met
0.7
​​Mar. 31 2025
-0.48
-0.48
-0.49
Missed
-1.9
Dec. 31 2024
-0.42
-0.43
-0.42
Beat
1.6​
Sep. 30 2024
-0.43
-0.43
-0.41
Beat
4.7
Jun. 30 2024
-0.39
-0.39
-0.45
Missed
-14.6
This summary was machine generated July 31 at 22:54 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)